Novigenix SA, leading Swiss biotech that develops and commercialises Immuno-Transcriptomic precision oncology solutions, today announced the election of Dr Miro Venturi to its Board of Directors. Dr Venturi is currently Group CEO of Sintetica SA, a Swiss-based multinational pharmaceutical company. He brings deep expertise in precision medicine, notably as former senior VP at Roche and Foundation Medicine.
Dr Brian Hashemi, executive chairman of Novigenix, said: ‘We are delighted to welcome Dr Venturi to the Board of Novigenix as we expand our biopharma partnerships and application of ImmunoTranscriptomic precision oncology solutions in drug development and clinical utility programs.’
‘Miro’s tremendous expertise in the development of novel biomarkers brings a valuable perspective in creating value along the patient journey, and we look forward to his contribution as we scale up the delivery of unique biopharma solutions to improve patient outcomes.’
Dr Miro Venturi, former senior VP, Global Head Diagnostics Biomarkers & Personalised Healthcare at Roche and Senior VP, Head Biopharma at Foundation Medicine, said: ‘Novigenix has already demonstrated the value of its ImmunoTranscriptomics platform for early detection of cancer, and the Team is now making great progress towards therapy response prediction and monitoring, based on data-driven immune insights.’
‘I am very much looking forward to supporting the team in delivering differentiated solutions that can significantly improve patient outcomes and the clinical utility of therapeutic modalities.’